Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
Noelle R, Lines J, Lewis L, Martell R, Guillaudeux T, Lee S, Mahoney K, Vesely M, Boyd-Kirkup J, Nambiar D, Scott A. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers In Oncology 2023, 13: 1225081. PMID: 37795437, PMCID: PMC10547146, DOI: 10.3389/fonc.2023.1225081.Commentaries, Editorials and LettersImmune checkpoint proteinsImmune checkpointsImmune systemT-lymphocyte antigen-4Cell death protein 1V-domain immunoglobulin suppressorDeath protein 1CD28 family membersAnti-VISTA antibodyT cell activationImportant homeostatic functionsVISTA blockadePD-1Proinflammatory changesImmune effectsMyeloid suppressionAntigen-4CTLA-4Immune cellsT cellsImmune responsePreclinical studiesClinical developmentHomeostatic functionsMyeloid lineageNormalization Cancer Immunotherapy for Melanoma
Vesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. Journal Of Investigative Dermatology 2020, 140: 1134-1142. PMID: 32092349, PMCID: PMC7247948, DOI: 10.1016/j.jid.2020.02.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNormalization cancer immunotherapyCancer immunotherapyImmune responseDysfunctional immune responseSystemic immune responsesContext of melanomaPatient survivalTreatment of cancerTumor responseImmunotherapyToxicity profileImmune systemTumor microenvironmentMelanomaCancerDistinct mechanismsResponseClinicians